Now that the top Gilead Sciences (GILD) executives are leaving, will a full-blown exodus occur at the biotech?

The thought arises after the company announced on Wednesday that Dr. Andrew Cheng, a 19-year Gilead veteran who was named chief medical office just five months ago, is suddenly departing. His resignation follows by just three weeks the unexpected news that chief executive John Milligan will leave at the end of the year, after just two years in that role, and that chairman John Martin will follow suit.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Could it be those execs can hear ‘the ticking’ … of that fabled ‘Bomb in Gilead?’ (apologies to the fans of Jeremiah 8:22)

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy